31/12/2025
As Innovent enters its 14th year, we look back with gratitude on a year of steady and meaningful progress in 2025. Our commercial portfolio expanded to 18 approved therapies, reflecting continued momentum across both our oncology and general biomedicine pipelines. Over the past year, we introduced important new medicines, including an anti-CTLA-4 immunotherapy, a dual-target metabolic therapy for weight management and glucose control, a therapy for thyroid eye disease, and a next-generation IL-23p19 inhibitor addressing inflammatory conditions. Each of these therapies is designed to address significant unmet clinical needs and expand high-quality treatment options for patients. We also increased patient access through the addition of several innovative medicines to China’s National Reimbursement Drug List. With appreciation for our colleagues, partners, and community, we look ahead to 2026 with focus and purpose, and remain committed to advancing innovation that improves patient health globally.
Wishing a joyful new year to all!
